Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sarepta Therapeutics buy melinda

Start price
€56.52
02.03.18 / 50%
Target price
€84.79
08.03.18
Performance (%)
17.79%
End price
€66.58
08.03.18
Summary
This prediction ended on 08.03.18 with a price of €66.58. The BUY prediction by melinda finished with a performance of 17.79%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Sarepta Therapeutics 0.493% 0.493% 7.043% 97.594%
iShares Core DAX® 4.015% 2.971% 16.492% 19.144%
iShares Nasdaq 100 2.755% 0.503% 40.029% 50.636%
iShares Nikkei 225® -0.826% -5.057% 14.566% 2.379%
iShares S&P 500 2.330% 0.720% 30.194% 44.181%

According to melinda what are the pros and cons of Sarepta Therapeutics for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Sarepta Therapeutics diskutieren
Prediction Buy
Perf. (%) 17.79%
Target price 84.788
Change
Ends at 08.03.18

$ SRPT hohe PT 94 $ 84 $ von Nomura



Beruf
Logo Sarepta Therapeutics Inc
Erforscht und entwickelt Behandlungen für Krankheiten und potenziell tödliche Viren

Sarepta Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der Entdeckung und Entwicklung von einzigartigen Therapien beschäftigt RNA für die Behandlung von seltenen Krankheiten Targeting und andere infektiöse.

Es konzentriert sich auf die Entwicklung ihrer Medikamentenkandidaten möglicherweise Krankheit DMD ändern.

Das Unternehmen wurde am 22. Juli 1980 gegründet und ist in Cambridge, MA ansässig.

Anzahl der Mitarbeiter: 197 Personen.



Prediction Buy
Perf. (%) 17.79%
Target price 84.788
Change
Ends at 08.03.18

(Vom Mitglied beendet)

Stopped prediction by melinda for Sarepta Therapeutics

buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€131.66
02.11.18
€144.32
04.11.21
-52.21%
26.03.21

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€119.00
15.10.18
€135.30
02.11.18
10.17%
02.11.18

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€91.74
16.06.18
€94.71
19.06.18
57.31%
19.06.18

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€51.03
08.10.17
€55.00
29.12.17
11.09%
29.12.17

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€46.03
08.10.17
€49.61
29.12.17
11.09%
29.12.17

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€36.98
20.07.17
€40.59
21.07.17
1.24%
21.07.17

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€41.00
20.07.17
€45.00
21.07.17
1.24%
21.07.17

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€32.56
11.01.17
€88.40
28.04.17
2.91%
28.04.17

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€23.54
23.08.16
€24.81
24.08.16
5.36%
24.08.16

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€18.50
09.06.16
€19.84
08.07.16
8.82%
08.07.16

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€16.64
03.05.16
€18.04
23.05.16
8.57%
23.05.16

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€7.49
23.04.16
€16.24
03.05.16
120.49%
03.05.16

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€14.88
14.03.16
€18.04
21.03.16
22.62%
21.03.16

Could be worthwhile Investment >10% per year
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€39.53
04.10.13
€41.00
04.04.14
-55.30%
04.04.14

Could be worthwhile Investment >10% per year